CONCLUSIONS: This is the first study to demonstrate safety and efficacy of intravesical incobotulinumtoxin A in patients with neurogenic or idiopathic detrusor overactivity. Incobotulinumtoxin A may be an attractive alternative to onabotulinumtoxin A, especially given its lower cost. Small sample size limits this data, however early results suggest improvements in quality of life and bladder dynamics. A larger, prospective study will be required to validate these findings.
INTRODUCTION AND OBJECTIVES: Following spinal cord injury (SCI), disruption to neuronal pathways of the bladder can lead to neurogenic detrusor over-activity (NDO) causing reduced capacity, high pressure and incontinence. Intra-detrusor injections of botulinum toxin A (BTX-A) are commonly used to manage these complications. Between 2013-2014 our department changed from using abobotulinum toxin (aboBTX) (750-1000 u) to onabotulinum toxin (onaBTX) (200 u) . We have analysed the urodynamic outcomes and patient satisfaction to determine the relative efficacy of the two drugs on NDO following SCI.
METHODS: The medical notes of 171 patients receiving consecutive doses of aboBTX and onaBTX during 2013-2014 were reviewed. 36 SCI patients with NDO and urodynamics within 6 months of injection of both aboBTX and onaBTX were included. The maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP) were recorded. Paired t-tests were performed to test difference in bladder function between the two BTX-A drugs.
RESULTS: The post-injection mean (AE SD) MCC for aboBTX was 375 AE 178 ml and for onaBTX was 378 AE 212 ml. The post injection mean (AE SD) MDP for aboBTX was 25 AE 21 cmH 2 O and for onaBTX was 27 AE 18 cmH 2 O. There was no significant difference between MCC (p¼0.5) and MDP (p¼0.86) for each drug. The scatter graphs demonstrate the relationship between the preparations with respect to MCC and MDP. The solid line represents the linear regression and the dashed line represents a 1:1 relationship. The linear regression for MCC had a slope of 1 demonstrating a clear correlation between the bladder capacity after aboBTX and onaBTX. There was not such a clear correlation between the MDP data. 12 out of 36 patients reported worse satisfaction with onaBTX than aboBTX, though interestingly this did not correlate with worse urodynamic outcomes.
CONCLUSIONS: There was no statistically significant difference in objectively measured urodynamic parameters of bladder function between aboBTX and onaBTX in patients with NDO following SCI. However 1/3 of patients reported worse satisfaction with onaBTX. The data will be further analysed to compare the efficacy of repeated injections and the effect of prior exposure to each agent.
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MP85-17 FACTORS ASSOCIATED WITH DURABILITY OF THERAPEUTIC BOTULINUM TOXIN A INJECTION FOR OVERACTIVE BLADDER
Kristian Stensland*, Burlington, MA; Jay Vance, Bennett Sluis, Boston, MA; Jared Schober, Arthur Mourtzinos, Lara Maclachlan, Burlington, MA INTRODUCTION AND OBJECTIVES: Patients suffering from overactive bladder (OAB) without response to behavioral and pharmaceutical intervention may opt for third-line therapy with botulinum toxin A injection. Botulinum injections have shown success in treating OAB urinary symptoms, but require repeat injections at an interval of 4-12 months. This study seeks to identify factors associated with the durability of this therapeutic effect.
METHODS: Patients undergoing treatment for OAB at Lahey Hospital and Medical Center between 2004 and 2016 were identified. Demographic, clinical and treatment data were extracted from patient charts. Patients were included if they had at least 1 botulinum injections. Time from initial to second botulinum injection was defined as therapeutic durability; time from initial injection to last clinic follow-up was defined and time to event analyses were employed: univariate analysis via log-rank method and multivariate Cox proportional hazards were used to identify associations with therapeutic durability. The multivariate Cox model comprised univariate factors with p values below 0.1 and a priori clinical variables. Significance was defined at the a¼ 0.05 level.
RESULTS: Of the available patients, 54 patients met inclusion criteria. Median time to repeat injection for those who had a second injection was 259 days (8.6 months). Kaplan-Meier survival estimated that 50% of patients required reinjection at 330 days (11 months). On univariate analysis, history of spinal cord injury (p ¼ 0.041), prostate cancer (p < 0.001), history of stroke/CVA (p¼0.037), and history of UTI (p¼0.013) were significantly associated with lower therapeutic durability. On multivariate analysis, only prostate cancer (OR 50.2, 95% CI 2.95-854, p ¼ 0.0068) and history of UTI (OR 4.11, 95% CI 1.10-15.3, p ¼ 0.035) were associated with lower therapeutic durability.
CONCLUSIONS: Botulinum injection showed a median durability of roughly 9 months. Patients with prostate cancer or a history of UTI had a statistically significantly lower durability of botulinum injection. Further study is warranted to identify further etiologic origins of these connections or elucidate other associated cofactors. Relevant data were extracted from patient charts. Patients were stratified by gender. Within groups, univariate analyses were conducted to identify factors associated with SNS treatment success. A multivariate model to predict SNS treatment success was also created within each group. The factors significantly associated with SNS treatment success were compared between groups to assess for effect modification.
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